Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes

This study has been completed.

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00543751

Purpose

The purpose of this study is to compare how MK0767 and metformin and sulfonylurea therapy lower blood glucose in patients with inadequate glycemic control This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Condition	Intervention	Phase
Diabetes Mellitus, Type 2	Drug: MK0767	Phase III

MedlinePlus related topics: Diabetes

Drug Information available for: Metformin Metformin hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Merck:

Study Start Date:	December 2002
Study Completion Date:	October 2004

Eligibility

Ages Eligible for Study:	21 Years to 78 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with Type 2 diabetes wtih inadequate glycemic control on maximally effective/tolerated metformin and sulfonylurea therapy
Non-pregnant females

Exclusion Criteria:

Patients with Type 1 Diabetes or history of ketoacidosis
Patients who have been treated with insulin or other antihyperglycemic agents
Patients with viral hepatitis, active liver or gallbladder disease, history of pancreatitis, heart disease, congestive heart failure, inadequately controlled hypertension, HIV positive, history hematologic disorders or neoplastic disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00543751

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

Study ID Numbers:	2007_634
Study First Received:	October 5, 2007
Last Updated:	October 12, 2007
ClinicalTrials.gov Identifier:	NCT00543751
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Metabolic Diseases
Metformin
Diabetes Mellitus, Type 2
Diabetes Mellitus

Endocrine System Diseases
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on January 15, 2009